ReviewInternational journal of nanomedicine2026
Plant-Derived Exosome-Like Nanoparticles: Mechanisms of Cross-Kingdom Regulation and Perspectives as Natural Drug Carriers for Disease Treatment.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Plant-Derived Exosome-Like Nanoparticles in Neurodegenerative Diseases: From Dual Bioactive-Delivery Roles to Translational Challenges.International journal of nanomedicine · 2026Review
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-derived exosome-like nanoparticles (PELNs) are membrane vesicles that are isolated from plant tissues, containing lipids, proteins, nucleic acids and various other natural bioactive components inside. Recent studies indicate that PELNs exhibit anti-inflammatory, antioxidant and anti-tumor functions, participate in intercellular communication and mediate cross-kingdom regulation. These nanoparticles demonstrate significant potential in the treatment of a variety of diseases, including malignancies, inflammatory bowel disease, cardiovascular disorders, and metabolic diseases. This review summarizes the biogenesis mechanisms, compositional elements and cross-kingdom regulatory functions of PELNs. Specifically, the 3' terminal 2'-O-methylation modification of plant miRNAs ensures their structural integrity and stability under harsh physiological conditions, facilitating efficient interspecies communication. Furthermore, as natural drug carriers, PELNs have substantial advantages in the targeted delivery of small-molecule drugs, nucleic acids and functional proteins. Finally, the current challenges and future development prospects of PELNs are discussed. Although research into PELNs remains at the initial stage, their potential applications in precision medicine and drug delivery systems are promising, offering novel strategies for future disease treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.